Trial reportRMD open2025
Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial.
Trial report in RMD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- The prediction of a good therapeutic response and outcome: at baseline or after a short term?Clinical rheumatology · 2026Article
- Cross-talk between aging resilience pathways and autoimmunity onset.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis study assessed the early effects of ozoralizumab (OZR) 30 mg in patients with rheumatoid arthritis (RA) with inadequate response to methotrexate (MTX-IR), drawing on OHZORA trial data for efficacy and safety insights.
methodsThe study included 141 patients with RA from the OHZORA trial, initiated on OZR 30 mg. The primary measure was the rate of achieving low disease activity (LDA) by the Clinical Disease Activity Index (CDAI) 3 days post-OZR initiation. Growth mixture modelling (GMM) of CDAI trajectories was performed to enable a more detailed analysis of the impact of OZR on disease activity improvement.
resultsThe retention rate of OZR up to 52 weeks was 87.9% (n=124). The LDA achievement rate on the third day of OZR introduction was 12.8% (n=18), and by week 52, 70.9% (n=100) had improved to LDA. Three distinct groups were identified using GMM: one group (n=78) reached LDA within 4 weeks of OZR initiation and maintained LDA up to week 52. Multiple logistic regression analysis revealed that both low baseline C-reactive protein (CRP) and low CDAI were independently associated with group membership.
conclusionOZR 30 mg demonstrated both immediate and sustained efficacy in MTX-IR patients with RA. Multivariate analysis suggested that both baseline inflammation and disease activity-represented by CRP and CDAI-may independently influence treatment response. However, residual confounding due to baseline disease activity cannot be completely excluded, and this remains a limitation of the present study.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.